Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List
--Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company’ s product toripalimab continues to be included in Category B in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity...